Effects of prostacyclin on bronchoconstriction and neutropenia induced by inhaled platelet-activating factor in man
- 30 April 1990
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 85 (4) , 763-769
- https://doi.org/10.1016/0091-6749(90)90196-b
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effect of platelet activating factor on leukocyte-endothelial cell interactionsThrombosis Research, 1988
- Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in manJournal of Allergy and Clinical Immunology, 1988
- Platelet-activating factor as a mediator of allergic diseaseJournal of Allergy and Clinical Immunology, 1988
- The Bronchoconstrictor Properties of Platelet-Activating Factor in HumansAmerican Review of Respiratory Disease, 1987
- Lung function and plasma levels of thromboxane B2, 6‐ketoprostaglandin F1 alpha and beta‐thromboglobulin in antigen‐induced asthma before and after indomethacin pretreatment.British Journal of Clinical Pharmacology, 1985
- The platelet‐independent release of thromboxane A2 by Paf‐acether from guinea‐pig lungs involves mechanisms distinct from those for leukotrieneBritish Journal of Pharmacology, 1984
- Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivativesEuropean Journal of Pharmacology, 1980
- Effects of intravenous infusion of prostacyclin (PGI2) in manProstaglandins, 1980
- Prevention of aspecifically induced bronchoconstriction by PGI2 and 20-methyl-PGI2 in asthmatic patientsPharmacological Research Communications, 1978
- Circulatory and anti-platelet effects of intravenous prostacyclin in healthy menPharmacological Research Communications, 1978